Equities research analysts forecast that Agios Pharmaceuticals Inc (NASDAQ:AGIO) will post $13.42 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Agios Pharmaceuticals’ earnings, with estimates ranging from $10.60 million to $17.00 million. Agios Pharmaceuticals reported sales of $10.51 million during the same quarter last year, which indicates a positive year-over-year growth rate of 27.7%. The business is scheduled to issue its next earnings results on Thursday, May 3rd.
According to Zacks, analysts expect that Agios Pharmaceuticals will report full year sales of $13.42 million for the current year, with estimates ranging from $58.30 million to $215.80 million. For the next year, analysts forecast that the company will post sales of $274.92 million per share, with estimates ranging from $85.66 million to $734.10 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Agios Pharmaceuticals.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.65) by ($0.16). The business had revenue of $9.80 million for the quarter, compared to the consensus estimate of $12.65 million. Agios Pharmaceuticals had a negative net margin of 731.60% and a negative return on equity of 76.67%. The business’s quarterly revenue was down 56.7% on a year-over-year basis. During the same period last year, the firm posted ($1.34) EPS.
A number of research firms have recently weighed in on AGIO. BidaskClub raised Agios Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 3rd. SunTrust Banks reaffirmed a “buy” rating and set a $101.00 price target (up previously from $80.00) on shares of Agios Pharmaceuticals in a report on Thursday, February 15th. JPMorgan Chase & Co. lifted their price target on Agios Pharmaceuticals from $76.00 to $85.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. Credit Suisse Group boosted their target price on Agios Pharmaceuticals from $66.00 to $80.00 and gave the stock an “outperform” rating in a report on Thursday, February 15th. They noted that the move was a valuation call. Finally, Needham & Company LLC boosted their target price on Agios Pharmaceuticals from $72.00 to $86.00 and gave the stock a “buy” rating in a report on Thursday, February 15th. Four investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $85.50.
Agios Pharmaceuticals (NASDAQ AGIO) traded down $0.17 on Friday, hitting $83.33. The stock had a trading volume of 237,701 shares, compared to its average volume of 450,344. The company has a market capitalization of $4,780.00, a PE ratio of -12.36 and a beta of 2.02. Agios Pharmaceuticals has a 52 week low of $45.11 and a 52 week high of $85.88.
In related news, insider Scott Biller sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 10th. The stock was sold at an average price of $65.00, for a total transaction of $195,000.00. Following the sale, the insider now owns 56,059 shares of the company’s stock, valued at $3,643,835. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Corp /De/ Celgene bought 851,154 shares of the company’s stock in a transaction that occurred on Tuesday, January 23rd. The shares were purchased at an average cost of $67.00 per share, for a total transaction of $57,027,318.00. Following the acquisition, the insider now owns 1,374,599 shares of the company’s stock, valued at $92,098,133. The disclosure for this purchase can be found here. In the last three months, insiders have sold 191,180 shares of company stock worth $14,758,309. 5.43% of the stock is owned by corporate insiders.
A number of large investors have recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Agios Pharmaceuticals by 41.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,600 shares of the biopharmaceutical company’s stock valued at $149,000 after buying an additional 762 shares in the last quarter. State of Alaska Department of Revenue bought a new position in shares of Agios Pharmaceuticals in the fourth quarter valued at $160,000. Bank of Montreal Can increased its holdings in shares of Agios Pharmaceuticals by 74.8% in the fourth quarter. Bank of Montreal Can now owns 3,551 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 1,520 shares in the last quarter. Teacher Retirement System of Texas bought a new position in shares of Agios Pharmaceuticals in the third quarter valued at $225,000. Finally, Macquarie Group Ltd. bought a new position in shares of Agios Pharmaceuticals in the third quarter valued at $245,000. 82.40% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/03/14/zacks-brokerages-expect-agios-pharmaceuticals-inc-agio-will-announce-quarterly-sales-of-13-42-million.html.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Get a free copy of the Zacks research report on Agios Pharmaceuticals (AGIO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.